<DOC>
	<DOCNO>NCT01559844</DOCNO>
	<brief_summary>The primary objective determine administration combination sofosbuvir ( SOF ; GS-7977 ; PSI-7977 ) ribavirin ( RBV ) HCV-infected adult hepatocellular carcinoma ( HCC ) meeting MILAN criterion prior undergo liver transplantation could prevent post-transplant re-infection determine sustained post-transplant virological response ( HCV RNA &lt; LLoQ ) 12 week post-transplant . Participants enroll pretransplant treatment phase ( 24 48 week ) . Participants enrol 24 week pretransplant treatment phase may receive treatment additional 24 week pretransplant retreatment phase . Participants enrol 48 week pretransplant treatment second baseline Week 24 combine analysis pretransplant retreatment phase . Participants undergo liver transplant stop study drug 24 hour prior transplant , enter 48-week follow-up phase monitor recurrent HCV infection .</brief_summary>
	<brief_title>Efficacy Sofosbuvir With Ribavirin Administered Pre-Transplant Preventing Hepatitis C Virus ( HCV ) Recurrence Post-Transplant</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . Willing able provide write informed consent 2 . Males female , age &gt; 18 year old 3 . Males must agree consistently correctly use condom female partner agree use approve form birth control date screen 7 month last dose ribavirin . 4 . Confirmation chronic HCV infection document least one measurement serum HCV RNA LLOQ measure screening , least one following : Positive antiHCV antibody test , HCV RNA HCV genotyping test least 6 month prior baseline/Day 1 visit together positive HCV RNA test antiHCV antibody time screening , Positive HCV RNA test antiHCV antibody test time screen together either liver biopsy consistent chronic HCV infection ( liver biopsy perform enrollment evidence chronic HCV infection , presence fibrosis ) 5 . HCV RNA &gt; 10^4 IU/mL screen 6 . Patients meet MILAN criterion undergo liver transplant HCC secondary HCV MELD &lt; 22 HCC weight MELD ≥ 22 . 7 . ChildPugh Score ( CPT ) ≤ 7 8 . Planned management subject meet United Network Organ Sharing ( UNOS ) criterion , image study make available review require . 9 . Has treat investigational drug device within 30 day screen visit . 1 . Females childbearing potential pregnant nursing 2 . Prior exposure directacting antiviral target HCV nonstructural ( NS ) 5B polymerase 3 . Any transplant patient agree liver transplant live donor . 4 . Participants require plan induction therapy biologics posttransplantation posttransplantation immunosuppressive regimen consistent follow within first 12 week posttransplant : Solumedrol/Prednisone ( taper approximately 7 day ) Tacrolimus ( maintain serum level 5 12 ng/mL ) Mycophenolate mofetil ( 2 g/day ) Introduction new maintenance immunosuppressant different list disallow except consultation first 12 week posttransplant 5 . Current , uncontrolled ascites , variceal hemorrhage , hepatic encephalopathy , hepatorenal syndrome hepatopulmonary syndrome , among sign decompensated cirrhosis . 6 . Chronic liver disease nonHCV etiology ( eg , hemochromatosis , Wilson 's disease , alpha1 antitrypsin deficiency , cholangitis ) 7 . Infection hepatitis B virus ( HBV ) HIV 8 . Contraindications RBV therapy 9 . Chronic use systemically administer immunosuppressive agent ( eg , prednisone equivalent &gt; 10 mg/day ) pretransplant treatment period . 10 . History previous solid organ transplantation 11 . Evidence renal impairment ( CLcr &lt; 60 mL/min ) calculate CockcroftGault equation . 12 . History current evidence psychiatric illness , immunologic disorder , hemoglobinopathy , pulmonary cardiac disease , porphyria , poorly control diabetes , cancer HCC , history malignancy opinion investigator make patient unsuitable study . Patients clinical sign symptom acute pancreatitis elevate lipase ( Screening screen period ) 13 . Known hypersensitivity RBV , study investigational medicinal product , metabolite , formulation excipients 14 . History receive systemic antineoplastic ( include sorafenib ) immunomodulatory treatment ( include radiation ) within 6 month prior first dose study drug expectation treatment need time study ( exclude local regional therapy TACE ) . 15 . Treatment Transcatheter arterial chemoembolization ( TACE ) radio frequency ablation ( RFA ) within 30 day prior first dose . 16 . Participation clinical study investigational drug , biologic , device within 3 month prior first dose administration baseline/Day 1 Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Chronic</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>transplant</keyword>
</DOC>